Table 2.
Ongoing Clinical Trials of TV in Patients with Recurrent or Advanced Cervical Cancer
| InnovaTV 20530 | InnovaTV 30129 | |
|---|---|---|
| Status | Active, non recruiting | Active, not recruiting |
| Phase | Ib/II | III |
| Setting | Recurrent or advanced cervical cancer | Recurrent or advanced cervical cancer |
| Patients enrolled | 214 | 482 |
| ORR (95% CI) | TV+beva 1L: 33%* TV+pembro 1L: 42%* TV+carbo 1L: 55%* TV+pembro 2L: 38%* TV+carbo+pembro+/-beva 1L: NA |
NA |
| mDOR months (95% CI) | TV+beva 1L: – TV+pembro 1L: NR TV+carbo 1L: 8.3* TV+pembro 2L: 13.8* TV+carbo+pembro+/-beva 1L: NA |
NA |
| mPFS months (95% CI) | – | NA |
| mOS months (95% CI) | – | NA |
Note: *Preliminary data.
Abbreviations: ORR, objective response rate; mDOR, median duration of response; mPFS, median progression free survival; mOS, median overall survival; NR, not reached; NA, data not yet available.